Obesity Clinical Trial
Official title:
Pathophysiological Study of Obesity-related Asthma
Asthma is more frequent in obese women, but the mechanisms underlying the causes of this increased frequency are unknown and are different from usual asthma pathophysiology (associated with allergy). Obesity is known to influence ventilation; our hypothesis is that the normal variability of ventilation is decreased in obese patients, and that this decrease is responsible for an increased reactivity of their airway to non specific stimuli. In this observational study, breathing variability will be studied using polygraphy (an investigation that is made in these women to detect nocturnal apneas), and airway reactivity is studied between pulmonary function tests that are made before bariatric surgery.
Background : An increase in asthma prevalence (or asthma-like symptoms) has been established
in obese subjects, especially women. The aim of this pathophysiological study is to evaluate
whether the modifications of respiratory mechanics due to severe obesity (Body Mass Index
[BMI]>35) may explain the increase in asthma prevalence. Our hypothesis is that a decrease
in variability of tidal breathing (evaluated by the coefficient of variation of Tidal
volume: CVTV) (which traduces a physiological response to the increased work of breathing)
associated with a decrease in the frequency of deep inhalations (FDI) (physiological sighs).
The bronchodilatory and bronchoprotective roles of these deep inhalations have been
demonstrated. The avoidance of deep inhalations during 10 minutes in healthy subjects is
responsible for a non specific transient airway hyperresponsiveness (AHR) to methacholine.
Consequently, obesity-related asthma could be due to the loss of bronchoprotective effect of
deep inhalations.
Aims: The aim of this study is to evaluate whether 1) the variability of their diurnal
ventilation (based on the measurement of CVTV and FDI) in three groups of women: obese with
AHR, obese without AHR and healthy non obese (main objective), 2) obesity-related asthma
pathophysiology is linked to atopy, and 3) obese asthmatic women have a greater decrease in
ventilation variability as compared to non asthmatic obese women (secondary objectives).
Methods: The prevalence of AHR and confirmed asthma (international clinical and functional
definition) are determined based on pulmonary function test (spirometry, volume
determinations, arterial blood gas, measurement of the resistance of the respiratory system
with evaluation of the response to deep inhalation, methacholine challenge, exhaled NO
measurement, nocturnal polygraphy and oeso-gastroscopy) results obtained from 150 obese (BMI
> 35). The FDI and CVTV will be determined based on the tidal volume obtained from thoracic
and abdominal plethysmography inductance measurements during the polygraphy. A nocturnal
polygraphy is systematically done in these women to search for a Sleep Apnea Syndrome. 30
healthy (non asthmatic, normal exhaled NO value, BMI 18.5 to 25) women will constitute a
control group. The size of the groups have been calculated based on literature data
concerning the FDI and CVTV.
Analysis criteria: The prevalences of asthma (or asthma-like symptoms) and AHR will be of
30% and 50% (based on a personal preliminary study), respectively. The FDI and CVTV will be
compared in obese women with and without AHR and in healthy women (primary objective), and
subsequently in obese asthmatic women and obese non asthmatic women. The measurement of
exhaled NO and the bronchomotor effect of deep inhalation will allow the determination of
underlying pathophysiology of obesity-related asthma (secondary objective).
Perspectives: If our hypothesis is verified, obesity treatment will become part of the
management of asthma in women.
;
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
| Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
| Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
| Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
| Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
| Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
| Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
| Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
| Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
| Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
| Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
| Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
| Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
| Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |